117 related articles for article (PubMed ID: 21882181)
1. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Kim JJ; Vaziri SA; Rini BI; Elson P; Garcia JA; Wirka R; Dreicer R; Ganapathi MK; Ganapathi R
Cancer; 2012 Apr; 118(7):1946-54. PubMed ID: 21882181
[TBL] [Abstract][Full Text] [Related]
2. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Schneider BP; Wang M; Radovich M; Sledge GW; Badve S; Thor A; Flockhart DA; Hancock B; Davidson N; Gralow J; Dickler M; Perez EA; Cobleigh M; Shenkier T; Edgerton S; Miller KD;
J Clin Oncol; 2008 Oct; 26(28):4672-8. PubMed ID: 18824714
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.
de Velasco G; Gray KP; Hamieh L; Urun Y; Carol HA; Fay AP; Signoretti S; Kwiatkowski DJ; McDermott DF; Freedman M; Pomerantz MM; Choueiri TK
Eur Urol Focus; 2016 Dec; 2(6):633-639. PubMed ID: 28723497
[TBL] [Abstract][Full Text] [Related]
4. Tislelizumab combined with sunitinib in the treatment of metastatic clear cell renal cell carcinoma with renal venous tumor thrombus: A case report and literature review.
Gao Z; Jin L; Lv H; Duan N; Zhang G; Ran Y; Xue B; Liu X
Urol Case Rep; 2024 May; 54():102722. PubMed ID: 38566821
[TBL] [Abstract][Full Text] [Related]
5. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.
Kim HR; Park HS; Kwon WS; Lee JH; Tanigawara Y; Lim SM; Kim HS; Shin SJ; Ahn JB; Rha SY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):825-35. PubMed ID: 24013576
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Eechoute K; van der Veldt AA; Oosting S; Kappers MH; Wessels JA; Gelderblom H; Guchelaar HJ; Reyners AK; van Herpen CM; Haanen JB; Mathijssen RH; Boven E
Clin Pharmacol Ther; 2012 Oct; 92(4):503-10. PubMed ID: 22948895
[TBL] [Abstract][Full Text] [Related]
8. Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System.
Barbieri MA; Sorbara EE; Russo G; Cicala G; Franchina T; Santarpia M; Silvestris N; Spina E
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980737
[TBL] [Abstract][Full Text] [Related]
9. Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies.
Guillaume Z; Auvray M; Vano Y; Oudard S; Helley D; Mauge L
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551652
[TBL] [Abstract][Full Text] [Related]
10. Genome-Wide Meta-Analysis Identifies Variants in
Diekstra MHM; Swen JJ; van der Zanden LFM; Vermeulen SH; Boven E; Mathijssen RHJ; Fukunaga K; Mushiroda T; Hongo F; Oosterwijk E; Cambon-Thomsen A; Castellano D; Fritsch A; Donas JG; Rodriguez-Antona C; Ruijtenbeek R; Radu MT; Eisen T; Junker K; Roessler M; Jaehde U; Miki T; Böhringer S; Kubo M; Kiemeney LALM; Guchelaar HJ
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740506
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity of Anti-Angiogenic Therapies.
Van Wynsberghe M; Flejeo J; Sakhi H; Ollero M; Sahali D; Izzedine H; Henique C
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33916159
[TBL] [Abstract][Full Text] [Related]
12. Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma.
Sun F; Chen Z; Yao P; Weng B; Liu Z; Cheng L
Front Pharmacol; 2021; 12():641075. PubMed ID: 33762959
[No Abstract] [Full Text] [Related]
13. The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma.
Song Y; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; He J; Huang J
Cancer Biol Med; 2021 Mar; 18(2):562-8. PubMed ID: 33724741
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.
Udagawa C; Zembutsu H
Cancer Sci; 2020 Oct; 111(10):3445-3457. PubMed ID: 32780457
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma.
Argentiero A; Solimando AG; Krebs M; Leone P; Susca N; Brunetti O; Racanelli V; Vacca A; Silvestris N
J Clin Med; 2020 May; 9(5):. PubMed ID: 32456352
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.
D'Aniello C; Berretta M; Cavaliere C; Rossetti S; Facchini BA; Iovane G; Mollo G; Capasso M; Pepa CD; Pesce L; D'Errico D; Buonerba C; Di Lorenzo G; Pisconti S; De Vita F; Facchini G
Front Oncol; 2019; 9():1400. PubMed ID: 31921657
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib-and-Chinese herbal medicine-based systematic treatment clinically cured a patient with multiple metastatic primary clear cell carcinoma of the liver: a case report.
Sun L; Chen H; Xiao Z; Guo W; Lin L
Onco Targets Ther; 2019; 12():2823-2828. PubMed ID: 31043795
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib.
Jiménez-Fonseca P; Martín MN; Carmona-Bayonas A; Calvo A; Fernández-Mateos J; Redrado M; Capdevila J; Lago NM; Lacasta A; Muñarriz J; Segura Á; Fuster J; Barón F; Llanos M; Serrano R; Castillo A; Cruz Hernández JJ; Grande E
Oncotarget; 2018 Dec; 9(97):36894-36905. PubMed ID: 30651923
[TBL] [Abstract][Full Text] [Related]
19. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
Guo J; Jin J; Oya M; Uemura H; Takahashi S; Tatsugami K; Rha SY; Lee JL; Chung J; Lim HY; Wu HC; Chang YH; Azad A; Davis ID; Carrasco-Alfonso MJ; Nanua B; Han J; Ahmad Q; Motzer R
J Hematol Oncol; 2018 May; 11(1):69. PubMed ID: 29788981
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.
Yamamoto K; Yano I
Med Oncol; 2018 Jan; 35(2):16. PubMed ID: 29302760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
